BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 9, 2025
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Biopharma money raised: Jan. 1-Dec. 15, 2022

Dec. 16, 2022
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma: 2022 vs. 2021 vs. 2020 vs. 2019

Dec. 16, 2022
Total raised in public, private and other financings of biopharma companies, comparing 2022 vs. 2021 vs. 2020 vs. 2019.
Read More
Cell research illustration

Upbeat Horizon, Prometheus news lifts drug developer stocks; Clovis nosedives

Dec. 15, 2022
By Karen Carey
Chatter about an impending acquisition of Horizon Therapeutics plc sent its shares soaring 61% throughout November, making it the best performing stock of the month among the 30 companies that are part of BioWorld’s Drug Developers Index (BDDI).
Read More
Bar chart, downward arrow

Biopharma deal activity slipping, M&As remain low

Dec. 13, 2022
By Karen Carey
While biopharma deal values were down year-over-year in November by 7.6%, that gap has now doubled, showing a 15.5% decline in values in 2022. There has been a significant slowdown in activity in the second half of the year. Values were up by 7% in early August 2022. All told, 1,422 deals, including licensings, joint ventures and collaborations, have brought the industry a potential $169.2 billion through the first week of December.
Read More

Med-tech gainers and losers for Dec. 5-9, 2022

Dec. 12, 2022
The top 10 med-tech stock gainers and losers for the week.
Read More

Biggest gainers and losers for the week of Dec. 5-9, 2022

Dec. 12, 2022
The top 10 biopharma stock gainers and losers for the week.
Read More

Biopharma money raised: Jan. 1-Dec. 8, 2022

Dec. 9, 2022
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma: 2022 vs. 2021 vs. 2020 vs. 2019

Dec. 9, 2022
Total raised in public, private and other financings of biopharma companies, comparing 2022 vs. 2021 vs. 2020 vs. 2019.
Read More
International currency symbols

Biopharma financings at $56B, well below several other years

Dec. 6, 2022
By Karen Carey
Biopharma financings are tracking only 3% below 2019’s full-year total, but the volume of activity is at its lowest point since 2017. With a total of $56.1 billion raised, 2022 is currently the sixth best financing year on record, but it is significantly behind some of the years that rank higher.
Read More
Kineret-box-and-syringe

Bebtelovimab out, Kineret in, as US and globe fight to end the pandemic

Dec. 6, 2022
By Karen Carey
The world is emerging from the COVID-19 pandemic, as both cases and deaths have remained consistently low in recent months, despite continuous mutation of the SARS-CoV-2 virus. Nevertheless, there is a shuffling of candidates in the arsenal as new variants bump once-effective therapies and the next generation of options enter the arena.
Read More
Previous 1 2 … 115 116 117 118 119 120 121 122 123 … 267 268 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 8, 2025.
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • Kidney disease illustration

    Prokidney produces positive phase II CKD data, thunderous stock surge

    BioWorld
    A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) and diabetes therapy, rilparencel....
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing